Collegium Pharmaceutical(COLL) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, the company achieved record net revenues of $780.6 million, representing a 24% year-over-year increase, and adjusted EBITDA of $460.5 million, up 15% year-over-year [25][31] - The company generated over $329 million in cash from operations in 2025 and ended the year with over $386 million in cash, an increase of approximately $224 million from the end of 2024 [7][31] - GAAP net income for the fourth quarter was $17 million, up 36% year-over-year, while full-year GAAP net income was $62.9 million, down 9% year-over-year due to a one-time loss on extinguishment of debt [29][30] Business Line Data and Key Metrics Changes - Jornay PM prescriptions grew by 20% year-over-year, generating $148.9 million in net revenue, up 48% compared to pro forma 2024 revenue [6][26] - The pain portfolio generated $631.7 million in 2025, up 6% year-over-year, with all three core pain medicines delivering full-year growth [7][21] - Belbuca net revenue was $221.7 million in 2025, up 5% year-over-year, while Xtampza ER net revenue was $199.3 million, up 4% year-over-year [26][27] Market Data and Key Metrics Changes - Jornay's market share of the long-acting branded methylphenidate market grew to nearly 26% in the fourth quarter, up 6.5 percentage points year-over-year [18] - The pediatric and adolescent segment, which represents about 80% of total prescriptions, grew 14% year-over-year, while the adult segment grew 24% year-over-year [18][19] - The company secured new formulary access under a major commercial healthcare plan, increasing Jornay's coverage by an estimated 4.5 million covered lives [21] Company Strategy and Development Direction - The company focuses on three strategic priorities: driving growth for Jornay PM, maximizing the durability of the pain portfolio, and strategically deploying capital to enhance shareholder value [4][10] - The company aims to expand and diversify its portfolio through business development, debt repayment, and opportunistic share repurchases [11][33] - The company is committed to maximizing the life cycle of its pain portfolio and ensuring medicines remain accessible to patients [9][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver near and long-term growth, emphasizing the strong financial foundation provided by the pain portfolio and the growth potential of Jornay [12][37] - The company expects total product revenues in 2026 to be in the range of $805 million to $825 million, reflecting a 4% increase year-over-year driven by Jornay growth and durable revenues from the pain portfolio [31][32] - Management noted that they do not foresee significant competitive developments that could impact Jornay demand, highlighting its differentiated delivery technology [41] Other Important Information - The company published its 2025 ESG report, showcasing its commitment to social responsibility alongside financial success [5] - The company closed a $980 million syndicated credit facility, improving interest rates and providing flexibility for future business development opportunities [8][34] Q&A Session Questions and Answers Question: What assumptions underlie 2026 Jornay guidance, and how should we think about factors that could lead to upside? - Management indicated that growth is expected to be driven by demand growth, with relative stability in gross to nets between 2025 and 2026 [40] Question: Have there been any competitive developments in the ADHD market that could potentially impact Jornay demand? - Management stated that they do not see any material changes in competitive dynamics that could impact Jornay demand, emphasizing its unique delivery technology [41] Question: Can you help us frame how you're thinking about the ramp to peak sales for Jornay? - Management noted that they have not previously discussed peak sales but expect to see the impact of expanded sales and marketing activities throughout 2026 [45] Question: How promotionally sensitive are Belbuca and Xtampza at this stage of their life cycle? - Management indicated that Belbuca and Xtampza are highly promotionally sensitive, and they will continue to invest in these products [47][48]